Table 1.
The characteristics of RCT studies.
| Study | Phase | Stage | Sample size | Age, Median (Range) | Male, n (%) | PD-L1 expression | Neoadjuvant treatment regimen | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Arms | N | Tumor cell < 1% | Tumor cell 1 to 49% | Tumor cell ≥ 50% | ||||||
| Heymach 202319(AEGEAN) | 3 | Stage IIA to IIIB NSCLC | Study | 366 | 65 (30–88) | 252 (68.9) | 122 (33.3) | 135 (36.9) | 109 (29.8) | Durvalumab + carboplatin and paclitaxel |
| Control | 374 | 65 (39–85) | 278 (74.3) | 125 (33.4) | 142 (38.0) | 107 (28.6) | Carboplatin + paclitaxel | |||
| Forde 202220(CheckMate-816) | 3 | Stage IB to IIIA NSCLC | Study | 179 | 64 (41–82) | 128 (71.5) | 78 (43.6) | 51 (28.5) | 38 (21.2) | Nivolumab + platinum-doublet chemotherapy |
| Control | 179 | 65 (34–84) | 127 (70.9) | 77 (43.0) | 47 (26.3) | 42 (23.5) | Platinum-doublet chemotherapy | |||
| Wakelee 202321(KEYNOTE-671) | 3 |
Stage II to IIIB NSCLC |
Study | 397 | 63 (26–83) | 279 (70.3) | 138 (34.8) | 127 (32.0) | 132 (33.2) | Pembrolizumab + platinum-doublet chemotherapy |
| Control | 400 | 64 (35–81) | 284 (71.0) | 151 (37.8) | 115 (28.8) | 134 (33.5) | Platinum-doublet chemotherapy | |||
| Provencio 202322(NADIM II) | 2 | Stage IIIA or IIIB NSCLC | Study | 57 | 63.4 (NA) | 36 (63.2) | 20 (35.1) | 19 (33.3) | 18 (31.6) | Nivolumab plus platinum-based chemotherapy |
| Control | 46 | 63.1 (NA) | 34 (73.9) | 10 (21.7) | 23 (50.0) | 13 (28.3) | Platinum-doublet chemotherapy | |||
| Lu 202423(Neotorch) | 3 | Stage II or III NSCLC | Study | 202 | 62 (56–65) | 181 (89.6) | 51 (25.3) | 69 (34.2) | 64 (31.7) | Toripalimab + platinum based chemotherapy |
| Control | 202 | 61 (56–65) | 189 (93.6) | 54 (26.7) | 68 (33.7) | 64 (31.7) | Platinum-based chemotherapy | |||
| Yue 202424(RATIONALE-315) | 3 |
Stage II to IIIA NSCLC |
Study | 226 | 62 (30–80) | 205 (90.7) | 89 (39.4) | NR | NR | Tislelizumab + platinum-based chemotherapy |
| Control | 227 | 63 (36–78) | 205 (90.3) | 84 (37.0) | NR | NR | Platinum-based chemotherapy | |||
| Lei 202325(TD-FOREKNOW) | 2 | Stage IIIA or IIIB NSCLC | Study | 43 | 61 (54–65) | 34 (79.1) | 7 (16.3) | NR | NR | Camrelizumab + platinum-based chemotherapy |
| Control | 45 | 61 (54–65) | 40 (88.9) | 8 (17.8) | NR | NR | Platinum-based chemotherapy | |||
| Cascone 202426(CheckMate 77T) | 3 | Stage IIA to IIIB NSCLC | Study | 229 | 66 (NA) | 167 (72.9) | 93 (40.6) | 83 (36.2) | 45 (19.7) | Nivolumab + platinum-doublet chemotherapy |
| Control | 232 | 66 (NA) | 160 (69.0) | 93 (40.1) | 76 (32.8) | 52 (22.4) | Platinum-doublet chemotherapy | |||
NSCLC, non-small-cell lung cancer; PD-L1, programmed cell death 1 ligand 1; NR, not reported; NA, not available; RCT, randomized controlled trial.